ZyVersa Therapeutics Q3 EPS $(0.09) Beats $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q3 EPS loss of $(0.09), surpassing the consensus estimate of $(0.16) by 43.75%. This represents an 83.64% improvement from the $(0.55) per share loss in the same quarter last year.
November 14, 2023 | 11:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics reported a smaller-than-expected Q3 loss per share, indicating a strong improvement over the previous year's results.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The significant improvement from the previous year's loss suggests operational progress and may further boost confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100